List view / Grid view
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine-300x278.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine.jpg)
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...
29 June 2016 | By Victoria White, Digital Content Producer
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
27 May 2016 | By Victoria White, Digital Content Producer
The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus...
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
14 April 2016 | By Victoria White, Digital Content Producer
AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
14 April 2016 | By Victoria White, Digital Content Producer
Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV...
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
26 February 2016 | By Victoria White
TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose...
